Evidence map›Paper›PMID 28970080›Full record

Trial reportEBioMedicine2017

Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial.

Yunda Huang, Giuseppe Pantaleo, Gonzalo Tapia, Brittany Sanchez, Lily Zhang, Monica Trondsen, Arnt-Ove Hovden, Richard Pollard, Jürgen Rockstroh, Mats Ökvist and 1 more

Open access · goldAbstract readClinical Trial, Phase IIControlled Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 5 countries.

Yunda HuangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, M2-C200, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA. Electronic address: yunda@scharp.org.
Giuseppe PantaleoCentre Hospitalier Universitaire Vaudois, Rue du Bugnon 46, BH10-527, CH-1011 Lausanne, Switzerland. Electronic address: Giuseppe.Pantaleo@chuv.ch.
Gonzalo TapiaCentre Hospitalier Universitaire Vaudois, Rue du Bugnon 46, BH10-527, CH-1011 Lausanne, Switzerland. Electronic address: Gonzalo.Tapia@chuv.ch.
Brittany SanchezVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, M2-C200, WA, USA. Electronic address: bprigmore@scharp.org.
Lily ZhangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, M2-C200, WA, USA. Electronic address: yzhang2@scharp.org.
Monica TrondsenBionor Pharma AS, P.O. Box 1477 Vika, NO-0116 Oslo, Norway. Electronic address: monica.trondsen@gmail.com.
Arnt-Ove HovdenBionor Pharma AS, P.O. Box 1477 Vika, NO-0116 Oslo, Norway. Electronic address: arntovehovden@gmail.com.
Richard PollardUniversity of California, Davis School of Medicine, 4150 V Street, Suite G500 PSSB, 95817 Sacramento, CA, USA. Electronic address: rbpollard@ucdavis.edu.
Jürgen RockstrohOberarzt an der Medizinischen Universitätsklinik, Innere-Rheuma-Tropen Ambulanz, Sigmund-Freud-Str. 25, 53105 Bonn, Venusberg, Germany. Electronic address: Juergen.Rockstroh@ukb.uni-bonn.de.
Mats ÖkvistBionor Pharma AS, P.O. Box 1477 Vika, NO-0116 Oslo, Norway. Electronic address: mo@bionorpharma.com.
Maja A SommerfeltBionor Pharma AS, P.O. Box 1477 Vika, NO-0116 Oslo, Norway. Electronic address: ms@bionorpharma.com.
Bionor (Norway) · NOInfectious Disease Research Institute · USUniversity Hospital of Lausanne · CHCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAUniversity of Bonn · DEUniversity of California, Davis · USVID Specialized University · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn a placebo-controlled trial of the peptide-based therapeutic HIV-1 p24

methodsAll analyses of week 28 responses and fold-changes relative to baseline considered per-protocol participants (Vacc-4x:placebo=72:32) resuming cART after week 40. Linear regression models with interaction tests were used. VE was estimated as the Vacc-4x-placebo difference in log

findingsA lower fold-change of CD4+ T-cell proliferation was associated with VE

interpretationThese exploratory analyses highlight the potential value of investigating biomarkers in T-cell proliferation supernatants for VE in clinical studies.

Indexed as

AdultAIDS VaccinesCD4 Lymphocyte CountCD4-Positive T-LymphocytesCell ProliferationFemaleHIV-1HIV InfectionsHumansImmunity, CellularInterleukin-6MaleMiddle AgedTreatment OutcomeTumor Necrosis Factor-alphaViral LoadAIDS VaccinesIL6 protein, humanInterleukin-6TNF protein, humanTumor Necrosis Factor-alphaVacc-4xAnalytical treatment interruption (ATI)CD4HIVImmune predictorsTherapeutic vaccineViral load

Identifiers

PMID28970080
PMCPMC5652289
OpenAlexW2759882827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.